ロード中...
Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab
Hepatitis B virus (HBV) reactivation in the setting of rituximab use is a potentially fatal but preventable safety event. The rate of HBV screening and proportion of patients at risk who receive antiviral prophylaxis in patients initiating rituximab is unknown. We analyzed electronic health record (...
保存先:
| 出版年: | Medicine (Baltimore) |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Health
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5380298/ https://ncbi.nlm.nih.gov/pubmed/28353614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000006528 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|